FWIW, I expect MNTA to re-base itself again around 9.50 area until next Q call. It's very unlikely we will get approval by end of this year when especially FDA has yet to fully disclose their report on heprain supply chain safety.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.